Laura P W Ranum,
Kitzman Family Professor Of Molecular Genetics And Microbiology; Director Center For NeuroGenetics
Department:
Molecular Genetics & Microbiology
Business Phone:
(352) 294-5209
Business Email:
ranum@ufl.edu
About Laura P W Ranum
Fun Fact: I love to hike and my favorite hike is the double tea house hike near Lake Louise, Canada. Our lab focuses on the role of Repeat Associated Non-ATG (RAN) translation, RNA gain of function and protein gain of function in repeat expansion disorders including amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA) types 5 and 8, myotonic dystrophy (DM) types 1 and 2, and Huntington’s disease (HD). Additionally, we continue to search for novel human disease genes. We are using high-throughput sequencing strategies to look for single-gene mutations that cause novel forms of ataxia, ALS, and neuropsychiatric diseases. Our scientific breakthroughs over the years have depended on partnerships with talented colleagues and students and with members of the community who participated in our research studies. Although much work remains, scientific advances have dramatically increased opportunities for drug development and clinical trials. Our goal is to perform cutting-edge research that will lead to improvements in diagnosis and treatments for neurological and neuromuscular disease.
Related Links:
Teaching Profile
Courses Taught
2018,2023-2024
GMS7980 Research for Doctoral Dissertation
2018,2022-2024
GMS7979 Advanced Research
2016-2017
GMS6750 Molecular Pathobiology of Neural Disease
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-9808-9661
Areas of Interest
- Amyotrophic Lateral Sclerosis
- Gene Discovery
- Genetics of Neurodegenerative Disease
- Multiple System Atrophy (MSA)
- Myotonic Dystrophy
- Neurodegenerative diseases
- Neuropathology of Neurodegenerative diseases
- Repeat Expansion Diseases
- Spinocerebellar Ataxia
Publications
2023
Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1
Brain.
146(10):4217-4232
[DOI] 10.1093/brain/awad148.
[PMID] 37143315.
2023
Machado-Joseph disease in a Sudanese family links East Africa to Portuguese families and allows reestimation of ancestral age of the Machado lineage
Human Genetics.
142(12):1747-1754
[DOI] 10.1007/s00439-023-02611-8.
[PMID] 37957369.
2022
RAN proteins in neurodegenerative disease: Repeating themes and unifying therapeutic strategies
Current Opinion in Neurobiology.
72:160-170
[DOI] 10.1016/j.conb.2021.11.001.
[PMID] 34953315.
2022
Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice
Neuron.
110(7):1173-1192.e7
[DOI] 10.1016/j.neuron.2022.01.006.
[PMID] 35114102.
2021
CCG•CGG interruptions in high penetrance SCA8 families increase RAN translation and protein toxicity
BioRx.
[DOI] 10.1101/2021.02.08.430311.
2021
CCG•CGG interruptions in high‐penetrance SCA8 families increase RAN translation and protein toxicity
EMBO Molecular Medicine.
13(11)
[DOI] 10.15252/emmm.202114095.
[PMID] 34632710.
2021
Repeat length increases disease penetrance and severity in C9orf72 ALS/FTD BAC transgenic mice
Human Molecular Genetics.
29(24):3900-3918
[DOI] 10.1093/hmg/ddaa279.
[PMID] 33378537.
2021
The alternative initiation factor eIF2A plays key role in RAN translation of myotonic dystrophy type 2 CCUG•CAGG repeats
Human Molecular Genetics.
30(11):1020-1029
[DOI] 10.1093/hmg/ddab098.
[PMID] 33856033.
2021
Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia
Current Opinion in Neurology.
34(5):748-755
[DOI] 10.1097/WCO.0000000000000984.
[PMID] 34392299.
2020
Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model.
Neuron.
105(4):645-662.e11
[DOI] 10.1016/j.neuron.2019.11.007.
[PMID] 31831332.
2020
Loss of MBNL1 induces RNA misprocessing in the thymus and peripheral blood.
Nature communications.
11(1)
[DOI] 10.1038/s41467-020-15962-x.
[PMID] 32332745.
2020
Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice
Proceedings of the National Academy of Sciences.
117(31):18591-18599
[DOI] 10.1073/pnas.2005748117.
[PMID] 32690681.
2020
Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs.
Neuron.
108(4):784-796.e3
[DOI] 10.1016/j.neuron.2020.09.009.
[PMID] 33022226.
2019
Repeat-Associated Non-ATG Translation: Molecular Mechanisms and Contribution to Neurological Disease.
Annual review of neuroscience.
42:227-247
[DOI] 10.1146/annurev-neuro-070918-050405.
[PMID] 30909783.
2019
Repeat-associated non-AUG (RAN) translation: insights from pathology.
Laboratory investigation; a journal of technical methods and pathology.
99(7):929-942
[DOI] 10.1038/s41374-019-0241-x.
[PMID] 30918326.
2018
All in the Family: Repeats and ALS/FTD.
Trends in neurosciences.
41(5):247-250
[DOI] 10.1016/j.tins.2018.03.010.
[PMID] 29703376.
2018
Altered levels of the splicing factor muscleblind modifies cerebral cortical function in mouse models of myotonic dystrophy.
Neurobiology of disease.
112:35-48
[DOI] 10.1016/j.nbd.2018.01.003.
[PMID] 29331264.
2018
Intron retention induced by microsatellite expansions as a disease biomarker.
Proceedings of the National Academy of Sciences of the United States of America.
115(16):4234-4239
[DOI] 10.1073/pnas.1716617115.
[PMID] 29610297.
2018
Repeat-associated non-ATG (RAN) translation.
The Journal of biological chemistry.
293(42):16127-16141
[DOI] 10.1074/jbc.R118.003237.
[PMID] 30213863.
2018
Repeat-Associated Non-ATG Translation in Neurological Diseases.
Cold Spring Harbor perspectives in biology.
10(12)
[DOI] 10.1101/cshperspect.a033019.
[PMID] 29891563.
2018
SCA 8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF 3F
The EMBO Journal.
37(19)
[DOI] 10.15252/embj.201899023.
[PMID] 30206144.
2017
A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.
PloS one.
12(5)
[DOI] 10.1371/journal.pone.0173565.
[PMID] 28467418.
2017
Mutant Huntingtin Disrupts the Nuclear Pore Complex.
Neuron.
94(1):93-107.e6
[DOI] 10.1016/j.neuron.2017.03.023.
[PMID] 28384479.
2017
New developments in RAN translation: insights from multiple diseases.
Current opinion in genetics & development.
44:125-134
[DOI] 10.1016/j.gde.2017.03.006.
[PMID] 28365506.
2017
RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.
Neuron.
95(6):1292-1305.e5
[DOI] 10.1016/j.neuron.2017.08.039.
[PMID] 28910618.
2016
C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD.
Neuron.
90(3):521-34
[DOI] 10.1016/j.neuron.2016.04.005.
[PMID] 27112499.
2015
Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells.
Stem cells (Dayton, Ohio).
33(6):1829-38
[DOI] 10.1002/stem.1970.
[PMID] 25702800.
2015
MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain.
Cell reports.
12(7):1159-68
[DOI] 10.1016/j.celrep.2015.07.029.
[PMID] 26257173.
2015
RAN Translation in Huntington Disease.
Neuron.
88(4):667-77
[DOI] 10.1016/j.neuron.2015.10.038.
[PMID] 26590344.
2014
Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion.
Neurobiology of aging.
35(10):2419.e17-21
[DOI] 10.1016/j.neurobiolaging.2014.04.009.
[PMID] 24819148.
2014
Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders.
Current opinion in genetics & development.
26:6-15
[DOI] 10.1016/j.gde.2014.03.002.
[PMID] 24852074.
2013
Compound Loss of Muscleblind-Like Function in Myotonic Dystrophy
Embo Molecular Medicine.
5:1887-1900
2013
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.
Proceedings of the National Academy of Sciences of the United States of America.
110(51):E4968-77
[DOI] 10.1073/pnas.1315438110.
[PMID] 24248382.
2013
Repeat-associated non-ATG (RAN) translation in neurological disease.
Human molecular genetics.
22(R1):R45-51
[DOI] 10.1093/hmg/ddt371.
[PMID] 23918658.
2013
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta neuropathologica.
126(1):39-50
[DOI] 10.1007/s00401-013-1123-8.
[PMID] 23666556.
2012
C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan.
Archives of neurology.
69(9):1154-8
[DOI] 10.1001/archneurol.2012.1219.
[PMID] 22637429.
2012
Clinical and genetic features of spinocerebellar ataxia type 8.
Handbook of clinical neurology.
103:493-505
[DOI] 10.1016/B978-0-444-51892-7.00031-0.
[PMID] 21827909.
2012
GGCCTG repeats put a hex on Purkinje cells and motor neurons in SCA36.
Neurology.
79(4):302-3
[DOI] 10.1212/WNL.0b013e31826043d9.
[PMID] 22744663.
2012
Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise.
Human molecular genetics.
21(21):4645-54
[DOI] 10.1093/hmg/dds306.
[PMID] 22846424.
2012
Mutational origin of Machado-Joseph disease in the Australian Aboriginal communities of Groote Eylandt and Yirrkala.
Archives of neurology.
69(6):746-51
[DOI] 10.1001/archneurol.2011.2504.
[PMID] 22351852.
2012
Spinocerebellar ataxia type 5.
Handbook of clinical neurology.
103:451-9
[DOI] 10.1016/B978-0-444-51892-7.00028-0.
[PMID] 21827906.
2011
Dutch myotonic dystrophy type 2 patients and a North-African DM2 family carry the common European founder haplotype.
European journal of human genetics : EJHG.
19(5):567-70
[DOI] 10.1038/ejhg.2010.233.
[PMID] 21224892.
2011
Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13).
PloS one.
6(3)
[DOI] 10.1371/journal.pone.0017811.
[PMID] 21479265.
2011
Non-ATG-initiated translation directed by microsatellite expansions.
Proceedings of the National Academy of Sciences of the United States of America.
108(1):260-5
[DOI] 10.1073/pnas.1013343108.
[PMID] 21173221.
2010
[Double the trouble: bidirectional expression of the SCA8 CAG/CTG expansion mutation – evidence for RNA and protein gain of function effects].
Rinsho shinkeigaku = Clinical neurology.
50(11):982-3
[PMID] 21921535.
2010
Molecular genetic advances in neurological disease: special review issue.
Human molecular genetics.
19(R1):R1-3
[DOI] 10.1093/hmg/ddq193.
[PMID] 20484169.
2010
Spectrin mutations that cause spinocerebellar ataxia type 5 impair axonal transport and induce neurodegeneration in Drosophila.
The Journal of cell biology.
189(1):143-58
[DOI] 10.1083/jcb.200905158.
[PMID] 20368622.
2009
RNA gain-of-function in spinocerebellar ataxia type 8.
PLoS genetics.
5(8)
[DOI] 10.1371/journal.pgen.1000600.
[PMID] 19680539.
2009
SNP haplotype mapping in a small ALS family.
PloS one.
4(5)
[DOI] 10.1371/journal.pone.0005687.
[PMID] 19479031.
2008
Mutagenic roles of DNA “repair” proteins in antibody diversity and disease-associated trinucleotide repeat instability.
DNA repair.
7(7):1135-54
[DOI] 10.1016/j.dnarep.2008.03.014.
[PMID] 18485833.
2007
Asian origin for the worldwide-spread mutational event in Machado-Joseph disease.
Archives of neurology.
64(10):1502-8
[PMID] 17923634.
2006
Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8.
Nature genetics.
38(7):758-69
[PMID] 16804541.
2006
DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression.
Human molecular genetics.
15(11):1808-15
[PMID] 16624843.
2006
Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation.
Journal of medical genetics.
43(6):527-30
[PMID] 16236810.
2006
RNA-mediated neuromuscular disorders.
Annual review of neuroscience.
29:259-77
[PMID] 16776586.
2006
Spectrin mutations cause spinocerebellar ataxia type 5.
Nature genetics.
38(2):184-90
[PMID] 16429157.
2005
Genetics and molecular pathogenesis of the myotonic dystrophies.
Current neurology and neuroscience reports.
5(1):55-9
[PMID] 15676109.
2005
RNA pathogenesis of the myotonic dystrophies.
Neuromuscular disorders : NMD.
15(1):5-16
[PMID] 15639115.
2004
Hairpin structure-forming propensity of the (CCTG.CAGG) tetranucleotide repeats contributes to the genetic instability associated with myotonic dystrophy type 2.
The Journal of biological chemistry.
279(40):41715-26
[PMID] 15292165.
2004
Myotonic dystrophy: RNA pathogenesis comes into focus.
American journal of human genetics.
74(5):793-804
[PMID] 15065017.
2004
Pathogenic RNA repeats: an expanding role in genetic disease.
Trends in genetics : TIG.
20(10):506-12
[PMID] 15363905.
2004
Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia.
American journal of human genetics.
75(1):3-16
[PMID] 15152344.
2003
Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract.
American journal of human genetics.
73(4):849-62
[PMID] 14505273.
2003
Repeat analysis pooled isolation and detection (RAPID) cloning of microsatellite expansions.
Methods in molecular biology (Clifton, N.J.).
217:61-71
[PMID] 12491921.
2002
Dominantly inherited, non-coding microsatellite expansion disorders.
Current opinion in genetics & development.
12(3):266-71
[PMID] 12076668.
2002
Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
Current neurology and neuroscience reports.
2(5):465-70
[PMID] 12169228.
2001
Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
Science (New York, N.Y.).
293(5531):864-7
[PMID] 11486088.
2000
SCA8 CTG repeat: en masse contractions in sperm and intergenerational sequence changes may play a role in reduced penetrance.
Human molecular genetics.
9(14):2125-30
[PMID] 10958651.
1999
A nonpathogenic GAAGGA repeat in the Friedreich gene: implications for pathogenesis.
Neurology.
53(8):1854-7
[PMID] 10563639.
1999
An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8)
Nature genetics.
21(4):379-84
[PMID] 10192387.
1999
Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2).
Neuromuscular disorders : NMD.
9(1):19-27
[PMID] 10063831.
1999
Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7.
Human molecular genetics.
8(9):1657-64
[PMID] 10441328.
Grants
Aug 2024
ACTIVE
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center
Role: Faculty
Funding: NATL INST OF HLTH NINDS
Apr 2024
ACTIVE
Contribution of Repeat Associated Non-AUG (RAN) Proteins in Friedreich's and Other Hereditary Ataxias
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Sep 2023
ACTIVE
Understanding and targeting common mechanisms of myotonic dystrophy types 1 and 2 using novel repeat expansion mouse models
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Sep 2023
ACTIVE
Safety of Metformin in C9orf72 ALS: Effects on RAN Proteins, Breathing, Imaging, and Metabolomic Outcome Measures
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
May 2023
ACTIVE
Anti-RAN targeting immunotherapy for C9orf72 ALS and genetically unknown RAN-positive sporadic ALS
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Mar 2023
ACTIVE
Repeat associated non-AUG (RAN) proteins in FA: contribution to disease and therapeutic opportunities
Role: Other
Funding: FRIEDREICHS ATAXIA RESEARCH ALLIANCE
Feb 2023
ACTIVE
An RNA-based nanoparticle vaccine approach for the prevention and treatment of C9orf72 ALS/FTD
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Dec 2022
ACTIVE
Safety & therapeutic potential of metformin for C9orf72 ALS
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Sep 2022
ACTIVE
Molecular effects of metformin, PKR and TBI on C9orf72 ALS/FTD
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2022
ACTIVE
Identifying and targeting novel repeat associated non-AUG (RAN) proteins in sporadic ALS
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Jul 2022
ACTIVE
Novel repeat associated non-AUG (RAN) proteins in sALS, sFTD and SBMA: shared pathological features and unifying therapeutic opportunities
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jan 2022
– Dec 2023
Characterization of a Novel BAC Transgenic Mouse Model for DM2
Role: Other
Funding: MYOTONIC DYSTROPHY FOU
Aug 2021
– Jul 2023
Using mitochondrial Ca2+ uptake as a therapeutic target for ALS
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2021
ACTIVE
Contribution of RAN proteins to HD, SCA3 other CAG.CTG expansion diseases
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Mar 2021
– Feb 2022
RAN proteins in sporadic ataxias and SCA8: diagnostic tools and therapeutic potential of metformin
Role: Other
Funding: NATL ATAXIA FOUNDATION
Sep 2020
– Jun 2023
Identifying and understanding the role of repeat RNAs and RAN proteins in Alzheimer's disease
Role: Other
Funding: NATL INST OF HLTH NIA
Apr 2020
– Mar 2021
An endobody vaccine against a combination of RAN proteins as a therapeutic approach in a C9 ALS BAC mouse model
Role: Principal Investigator
Funding: JOHNS HOPKINS UNIVERSITY
Jan 2020
– Jan 2023
Provenance Initiatives Fund at the Center for NeuroGenetics
Role: Principal Investigator
Funding: UF FOUNDATION
Nov 2019
– Oct 2021
C9ORF72 ALS: Endobody vaccine for the treatment of C9 ALS/FTD
Role: Other
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Sep 2019
– Sep 2022
Therapeutic Potential of Metformin, an FDA-approved drug, and PKR Targeting for C9orf72 ALS
Role: Principal Investigator
Funding: US ARMY MED RES AND DEVELOPMENT COMMAND
Dec 2018
– Jan 2021
Presymptomatic biomarkers of C9-ALS/FTD
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Sep 2018
– Apr 2020
Assessment of endobody vaccine for effectiveness and ability to generate C9 RAN antibodies
Role: Principal Investigator
Funding: UNITED NEUROSCIENCE LIMITED
Aug 2018
– Jul 2021
The contribution of RAN proteins to C9ORF72 ALS/FTD
Role: Principal Investigator
Funding: MUSCULAR DYSTROPHY ASSO
Aug 2018
– Feb 2021
C9ORF72 ALS: Proof of biology for antibody treatment in C9-ALS mouse model
Role: Principal Investigator
Funding: BIOGEN MA INC
Feb 2018
– Feb 2020
Therapeutic potential of CRISPR-Cas9 in C9ORF72-repeat deletion strategy in C9ORF72 BAC transgenic mice
Role: Principal Investigator
Funding: CRISPR THERAPEUTICS AG
Jan 2018
– Dec 2019
Molecular characterization of RNA and RAN protein effects in DM2
Role: Other
Funding: WYCK FOUNDATION
Jul 2017
– Jun 2022
Neurodegenerative disease research
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2017
ACTIVE
University of Florida/National Ataxia Foundation Brain Donation Program
Role: Principal Investigator
Funding: NATL ATAXIA FOUNDATION
May 2017
– Dec 2020
Therapeutic potential of CRISPR-Cas9 in C9ORF72 ALS/FTD-repeat deletion and transcriptional repression strategies in humanized C9ORF72 BAC transgenic mice
Role: Principal Investigator
Funding: TARGET ALS FOUNDATION
via CRISPR THERAPEUTICS AG
Jan 2017
– Jun 2020
Developing human-derived antibodies to target dipeptide-repeat protein toxicity in C9orf72 disease
Role: Principal Investigator
Funding: TARGET ALS FOUNDATION
Jan 2017
– Jun 2020
Nuclear Export Inhibitor KPT-350 for C9orf72 and Sporadic ALS
Role: Principal Investigator
Funding: TARGET ALS FOUNDATION
Aug 2016
– Jun 2022
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Aug 2016
– Jul 2018
Molecular characterization & antibody therapy in a novel C9orf72 BAC mouse model
Role: Principal Investigator
Funding: MUSCULAR DYSTROPHY ASSO
Aug 2016
– Oct 2017
Developing a high-throughput screening assay for identification of small molecules that selectively target transcription of G4C2/G2C4 repeat expansions in the gene C9ORF72 in ALS
Role: Other
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Mar 2016
– Mar 2018
The Therapeutic Efficacy of Neurimmunes Human Derived Recombinant Antibodies in C9orf72 Transgenic Mouse Models
Role: Principal Investigator
Funding: NEURIMMUNE AG
Mar 2016
– Apr 2021
neurodegenerative disease research
Role: Principal Investigator
Funding: UF FOUNDATION
Jan 2016
– Jun 2023
Molecular genetic characterization of SCA8
Role: Principal Investigator
Funding: UF FOUNDATION
Jan 2016
– Jul 2022
Molecular Genetics of the G4C2 expansion mutation in ALS/FTD
Role: Principal Investigator
Funding: UF FOUNDATION
Jan 2016
– Dec 2016
ASO targeting of bidirectional transcripts and RAN translation in SCA8
Role: Principal Investigator
Funding: NATL ATAXIA FOUNDATION
Dec 2015
– Dec 2020
Brainstorming microsatellite expansion diseases symposium
Role: Principal Investigator
Funding: UF FOUNDATION
Aug 2015
– Jul 2023
Molecular Genetic Characterization of SCA8
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jan 2015
– Jan 2018
MBI Research Program MGOLD1
Role: Principal Investigator
Funding: UF FOUNDATION
Sep 2013
– Jun 2019
Myotonic Dystrophy: Molecular Pathophysiology and CNS Effects
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2013
– Jun 2023
Center for NeuroGenetics
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2013
– Jun 2019
Matching Funds for PPG Project Titled: "Myotonic Dystrophy: Molecular Pathophysiology and CNS Effects"
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO
May 2013
– Apr 2016
Repeat associated non-ATG (RAN) Translation in C9ORF72 ALS/FTD
Role: Principal Investigator
Funding: COLUMBIA UNIVERSITY
Contact Details
Phones:
- Business:
- (352) 294-5209
Emails:
- Business:
- ranum@ufl.edu
Addresses:
- Business Mailing:
-
2033 MOWRY RD
GAINESVILLE FL 32610 - Business Street:
-
PO BOX 103610
GAINESVILLE FL 32610